Effective monitoring of online reputation in the pharmaceutical industry

For pharmaceutical, biotech, medtech, and healthcare organizations, the difference is not determined by the number of mentions collected. What matters is the ability to assign the correct meaning to each piece of content, activate the appropriate process, and document the actions taken. Clarity in the decision-making pathway is a safety measure: it reduces the risk of improvised responses, delays in managing relevant cases, and misalignment between internal functions.

Why digital reputation requires scientific oversight

In online conversations, the boundary between an opinion, a question, and a report can be subtle. A user describing an adverse effect associated with a medicinal product, even without using precise clinical terminology, may generate information that should be evaluated according to pharmacovigilance procedures. Similarly, a question regarding indications, instructions for use, or interactions should not be treated as a routine customer care inquiry when it requires a balanced scientific response consistent with approved information.

Digital platforms make this scenario more complex. Content may be incomplete, written by a caregiver, reposted by other profiles, or published in environments that change rapidly. Automated screening can help identify keywords and trends, but it cannot replace human evaluation. Colloquial expressions, irony, misspelled brand names, and indirect references to a product generate false positives and, more importantly, potential omissions.

There is also a reputational issue specific to the life sciences sector: correcting inaccurate information must not become out-of-context promotional communication. Any public interaction must respect the approved framework, the nature of the channel, company procedures, and the distinction between scientific information, corporate communication, and safety case management. For this reason, monitoring should be built on shared governance rather than being an isolated marketing or communications activity.

Monitoring pharmaceutical online reputation: what to observe

An effective program begins by defining its scope. Not all sources have the same relevance, nor do they require the same monitoring frequency. Corporate social media channels, e-commerce pages, forums, patient communities, review websites, digital media, and editorial content may all have different dynamics. Selection depends on the portfolio, therapeutic area, markets involved, type of stakeholder, and the presence of campaigns or product launches.

Monitoring should include the company name, brands, device names, common variations, product classes, and, where justified, relevant clinical topics. Active substance names, competitors, or disease names may also be included when the scope is proportionate to the objectives and clear rules are in place regarding the management of collected information.

Quantitative data remain useful. Mention volume, trends over time, the most active sources, and the speed of information spread help identify anomalies. However, for a life sciences company, the operational priority is qualitative. A single mention may require immediate attention if it contains elements related to an adverse event, a technical complaint, or a potential quality issue. Conversely, a surge in negative comments may be reputationally significant without generating any pharmacovigilance obligations. These are different workflows that must communicate with one another without being confused.

From identification to classification

The key step is triage. Each identified item of content should be evaluated and classified according to predefined operational categories: medical information request, potential adverse event, product complaint, misinformation, reputational comment, access issue, or communication-related topic. The classification process should include explicit criteria, practical examples, and priority levels.

In the case of a potential safety report, monitoring does not replace the pharmacovigilance system. It represents a possible entry point into that system. The information should be routed within established timelines to the appropriate functions, including evidence of the source, date of identification, available text, and actions taken. Data retention and processing should follow company procedures, applicable obligations, and data minimization principles, including careful consideration of personal information published by users.

For medical inquiries, the process should involve Medical Information and personnel authorized to prepare accurate, non-promotional responses supported by relevant documentation. Public responses are not always appropriate. In some situations, it is preferable to invite the individual to use a suitable channel that protects confidentiality and allows complete management of the request. A decision not to respond should nevertheless be documented and justified rather than resulting from uncertainty regarding responsibility.

A process that connects functions and responsibilities

The quality of the monitoring framework depends on clear responsibilities. A sustainable operating model defines who observes the sources, who performs the initial assessment, who decides on escalation, who approves responses, and who maintains documentation. Procedures should also specify response timelines, contact channels, case closure criteria, and out-of-hours management where the risk profile requires it.

The involvement of multiple functions should not slow the process. On the contrary, a well-designed escalation matrix prevents redundant steps. Pharmacovigilance evaluates safety information; Medical Information manages scientific inquiries; Quality and technical functions assess complaints and potential defects; Regulatory Affairs verifies communication boundaries; Communications and Marketing contribute to understanding the reputational context. Decisions remain consistent when each function operates within its area of responsibility using shared terminology and documentation.

Outsourcing can be useful when volumes fluctuate, broader coverage is required, or internal teams need specialized expertise without permanently increasing headcount. In these situations, the partner should operate as a qualified extension of the company through product and procedure training, controlled access to tools, agreed response times, auditable activities, and clear boundaries regarding company-owned decisions. Eureka InfoMed integrates expertise in Medical Information, Pharmacovigilance, Medical Writing, and Quality to support processes that require continuity between scientific evaluation, documentation, and operational management.

Useful technology, but not sufficient

Social listening platforms are effective for aggregating sources, creating queries, identifying spikes, and generating dashboards. Their value, however, depends on configuration. A query that is too broad creates noise and increases review workload; a query that is too narrow risks excluding meaningful conversations. Keywords should be reviewed periodically, taking into account new product launches, changes in user language, and findings from manual review.

Artificial intelligence can support prioritization and preliminary content analysis, but it should not independently determine whether a case is a pharmacovigilance matter, whether a response is compliant, or whether information is scientifically accurate. In regulated environments, automation requires validation, qualified oversight, and a documented assessment of tool limitations. The goal is not to use more technology, but to use technology that is appropriate to the risk and controllable over time.

Metrics that measure control, not just visibility

A report intended for management and operational functions should not focus solely on the proportion of positive or negative sentiment. It should also show content distribution by category, the time from identification to escalation, compliance with service-level agreements, the number of cases referred to relevant functions, the sources generating the greatest exposure, and recurring themes.

It is equally useful to analyze outcomes: which questions recur most frequently, which content generates misunderstandings, where complaints or distorted perceptions are concentrated, and which informational materials could prevent future requests. Monitoring then becomes a structured source of evidence for improving scientific communication, internal training, and touchpoint management.

Reputation is not protected by deleting every critical comment or responding to every mention. It is protected through a system capable of distinguishing, evaluating, and acting rigorously. When digital listening, scientific expertise, and compliance operate within the same process, even a complex conversation can become an opportunity to demonstrate reliability.

Sources

1. European Medicines Agency (EMA). Good Pharmacovigilance Practices (GVP), Module VI – Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products.
2. European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP), Module IX – Signal Management.
3. Association of the British Pharmaceutical Industry (ABPI). Guidance on the Management of Information from Digital Media and Social Media in Pharmacovigilance.
4. European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA Code of Practice.